Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

ClinicalTrials.gov ID: NCT00127881

Public ClinicalTrials.gov record NCT00127881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy

Study identification

NCT ID: NCT00127881
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Emergent Product Development Seattle LLC; Industry
Enrollment: 76 participants

Conditions and interventions

Conditions

Interventions

HuMax-CD4 (zanolimumab) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2005
Primary completion: Jan 31, 2014
Completion: Not listed
Last update posted: Jul 25, 2012

Started 2005

United States locations

U.S. sites: 19
U.S. states: 16
U.S. cities: 18

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	—	—
Stanford University Medical Center	Stanford	California	94305	—
University of Colorado	Aurora	Colorado	80045	—
H. Lee Moffitt Cancer Center	Tampa	Florida	33612	—
The Emory Clinic	Atlanta	Georgia	30322	—
Northwestern University	Chicago	Illinois	60611	—
Tulane University Health Science Center	New Orleans	Louisiana	70112	—
Boston Medical Center	Boston	Massachusetts	02118	—
University of Michigan Medical Center	Ann Arbor	Michigan	48109	—
New York Medical Center	New York	New York	10016	—
Memorial Sloan Kettering	New York	New York	10021	—
SUNY Upstate Medical University	Syracuse	New York	13210	—
Duke University Medical Center	Durham	North Carolina	27710	—
University Hospital of Cleveland	Cleveland	Ohio	44106	—
Ohio State University	Columbus	Ohio	43201	—
Oregon Health & Science University	Portland	Oregon	97239	—
University of Pennsylvania Health System	Philadelphia	Pennsylvania	19104	—
Middle Tennessee Research Institute	Nashville	Tennessee	37212-2637	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00127881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 25, 2012 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00127881 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →